Programme Overview

ILCA 2019 / Programme Overview
General Session
State-of-the-Art Lecture
Industry Symposium

13:00 – 18:15

ILCA Pre-Conference Workshop on Metabolism and Liver Cancer: From Mechanism to Treatment

Chairs: Valerie Paradis, MD, PhD (France), Jean-François Dufour, MD, PhD (Switzerland) and Amit Singal, MD (USA)

13:00 – 13:25

  • Role of the Immune System in NAFLD Related Hepatocarcinogenesis
    Tim Greten, MD (USA)

13:25 – 13:50

  • Mouse Models and Lessons Learned for HCC in NAFLD
    Shabnam Shalapour, PhD (USA)

13:50 – 14:15

  • Molecular Characterisation of HCC in NAFLD
    Josep M. Llovet, MD, PhD (Spain/USA)

14:15 – 14:35

Panel Discussion

14:35 – 15:00

  • Assessment of Risk for HCC in NAFLD Patients
    Jean-Francois Dufour, MD, PhD (Switzerland)

15:00 – 15:25

  • The Attributable Fraction of NAFLD and Related Disorders to Hepatocellular Carcinoma in the U.S
    Katherine McGlynn, PhD (USA)

15:25- 15:50

  • Locoregional Therapies − Including Ablation − for HCC in Patients with NAFLD
    Anja Lachenmayer, MD (Switzerland)

15:50 – 16:15

  • Resection and Transplant for HCC in Patients with NAFLD
    Julie Heimbach, MD (USA)

16:15 – 16:35

Panel Discussion

16:35 – 17:00

  • Issues with Surveillance in NASH Population
    Amit Singal, MD (USA)

17:00 – 17:25

  • Pathologic Characterization of HCC in NASH and Impact on Biomarker Discovery/Therapeutics
    Valerie Paradis, MD, PhD (France)

17:25 – 17:50

  • Future Directions in Imaging and Biomarker-Based HCC Surveillance in NAFLD-Related Liver Disease
    Sven Francque, MD, PhD (Belgium)

17:50 – 18:15

Panel Discussion

The pre-conference workshop is subject to an additional registration. To attend this workshop, full conference registration is compulsory.

18:30 – 19:30

Young Investigator Session

Chairs: Maria Reig, MD, PhD (Spain) and Jean-Charles Nault, MD (France)

  • How to Publish in Journal of Hepatology?
    Bruno Sangro, MD, PhD (Spain)
  • 4 oral presentations by young researchers

0-28 Metabolomic Landscapes of Non-Alcoholic Fatty Liver-Associated Hepatocellular Carcinoma and its Diagnostic Potential

Monika Lewinska et al. 

0-29 PVRL1/TIGIT Represents a Novel Molecular Mechanism for PD1 Blockade Resistance in Hepatocellular Carcinoma

Carmen Chak-Lui Wong et al. 

0-30 Effect of the Microbiota on the Peripheral Immune Response in Patients with NAFLD-Associated Hepatocellular Carcinoma

Jason Behary et al. 

0-31 Evaluation of the AFP Model in Patients with Low Risk Recurrence Profile: Further Evidence to Support its Inclusion for Candidate’s Selection

Federico Piñero et al. 

08:00 – 09:30

ILCA Symposium 1: The Cell of Origin of Liver Cancer

Chairs: Anurada Budhu, PhD (USA) and Augusto Villanueva, MD, PhD (USA)

  • Hepatocytes, Cholangiocytes, Stem Cells, etc. Who to Blame for Liver Cancer Development?
    Lars Zender, MD, PhD (Germany)
  • Why Inflammation and Regeneration are Key to Liver Cancer Development?
    Nabil Djouder, PhD (Spain)
  • Cell of Origin in Human Samples: Lessons from Genomic Studies
    Anuradha Budhu, PhD (USA)

09:30 – 10:15

State-of-the-Art Lecture 1: The Patient Perspective on Cancer Treatment

Chair: Morris Sherman, MD, PhD (Canada)
Speaker: Melinda Bachini (USA)

10:15 – 10:45

Coffee and Networking Break

10:45 – 11:00

Welcome Address

Morris Sherman, MD, PhD (Canada), Jessica Zucman-Rossi, MD, PhD (France), Sandrine Faivre, MD, PhD (France) and Bruno Sangro, MD, PhD (Spain)

11:00 – 12:30

General Session 1: Molecular Pathogenesis

Chairs: Stefano Caruso, PhD (France) and Gregory Gores, MD (USA)
0-07 TYRO3 Plays a Pivotal Role in the Hepatitis-Mediated Tumorigenesis: A Potential Therapeutic Target for Liver Cancers
Sen-Yung Hsieh et al.
0-08 The Imprinted DLK1/DIO3 Locus as a Key Player in β-Catenin Driven Tumorigenesis
Angélique Gougelet et al.
0-09 Unique Molecular Traits for NASH-Related Hepatocellular Carcinoma
Sara Torrecilla et al.
0-10 Characterization of Hepatitis B Virus-related Insertional Mutagenesis in Hepatocellular Carcinomas from European and African patients
Camille Peneau et al.
0-11 Differential role of Hippo cascade in c-Met/β-catenin and c-Met/sgAxin1 driven mouse HCC
Haichuan Wang et al.
0-12 A novel immunogenic mouse model of hepatocellular carcinoma for studying mechanisms of immune escape and response to immunotherapies
Amaia Lujambio et al.

12:30 – 12:45

Session Break

12:45 – 14:15

Industry Partner Lunch Symposium

14:15 – 14:30

Session Break

14:30 – 16:00

General Session 2: Clinical Trials

Chairs: Kathryn McGlynn,PhD (USA) and David Pinato, MD MRCP (UK)
0-13 Safety Profile of Nivolumab (NIVO) Plus Ipilimumab (IPI) Combination Therapy in Patients (pts) With Advanced Hepatocellular Carcinoma (HCC) in the CheckMate 040 Study
Anthony B. El-Khoueiry et al.
0-14 Alpha-fetoprotein (AFP) response and efficacy outcomes in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
Robin Katie Kelley et al.
0-15 Multicentric Prospective Study Of Validation Of Angiogenesis-Related Gene Polymorphisms In Hepatocellular Carcinoma Patients Treated With Sorafenib: Final Results Of Innovate Study
Andrea Casadei Gardini et al.
0-16 Economic Analysis of Open Versus Minimally-Invasive Hepatectomy: A Systematic Review and Meta-Analysis
Ioannis A Ziogas et al.
0-17 A multi-national, Multi-Institutional Study of Comparing an Efficacy of Stereotactic Body Radiation Therapy and Radiofrequency Ablation for Hepatocellular Carcinoma
Jinsil Seong et al.
0-32 Phase Ib Study Results: Safety and Efficacy of Atezolizumab + Bevacizumab Versus Atezolizumab in Patients with Previously Untreated, Unresectable or Advanced
Kyung-Hun Lee et al.

16:00 – 16:45

Coffee and Networking Break

16:00 – 16:45

ILCA General Assembly (members only)

16:45 – 18:15

ILCA Symposium 2: Peri Hilar Cholangiocarcinoma

Chairs: Eric Vibert, MD, PhD (France) and Christian Toso, MD, PhD (Switzerland)

  • Patient Selection and Optimization for Surgery
    Masato Nagino, MD (Japan)
  • Resection or Transplantation for Cholangiocarcinoma
    Julie Heimbach, MD (USA)
  • Histological and Morphological Heterogeneity of Biliary Stenosis
    Kristen Muri Boberg, MD, PhD (Norway)

18:15 – 19:15

Industry Partner Symposium

19:15 – 20:00

Welcome Reception

07:30 – 08:30

Industry Partner Symposium

08:30 – 9:45

ILCA − EASL Symposium

  • Assessment of Risk and Decision Analysis
    Pierre Nahon, MD, PhD (France)
  • Risk Assessment for Outcomes Following Potentially Curative Treatments for HCC
    Francis Yao, MD (USA)
  • Assessing Risk of Bad Outcomes Following TACE and Systemic Therapy
    Maria Reig, MD, PhD (Spain)

09:45 – 10:45

Networking Break and e-Poster Viewing Tour

10:45 – 12:15

Presidential Session

Chairs: Morris Sherman, MD, PhD (Canada), Jessica Zucman-Rossi, MD, PhD (France), Sandrine Faivre, MD, PhD (France) and Bruno Sangro, MD, PhD (Spain)

0-01 Results of a Phase 3 Study of Pembrolizumab Versus Best Supportive Care for Second-Line Therapy in Advanced Hepatocellular Carcinoma: KEYNOTE-240
Richard Finn et al.
0-02 Randomized, Open-Label, Perioperative Phase II Study Evaluating Nivolumab Alone or Nivolumab Plus Ipilimumab in Patients with Resectable HCC
Ahmed Kaseb et al.
0-03 Profiling of Routine serum parameters and APP Evolution in Cirrhosis Following HCV Eradication for Stratification of HCC risk: A Trajectory Clustering Analysis from the ANRS CO12 CirVir Cohort
Pierre Nahon et al.
0-04 Mri Radiomics Features Predict Immuno-Oncological Characteristics and Recurrence of Hepatocellular Carcinoma
Stefanie Hectors et al.
0-05 Identification of A Pan-Gamma-Secretase Inhibitor Response Signature for Notch-Driven Cholangiocarcinoma
Colm Joseph O Rourke et al.
0-06 Genomic Analysis of Hepatocellular Carcinoma with Active Hepatitis B Virus Replication
Huat Chye Lim et al.

12:15 – 13:45

Industry Partner Lunch Symposium

13:45 – 14:00

Session Break

14:00 – 15:15

Grand Rounds Session

Multidisciplinary Case Presentations and Debate
Chair: Laura Kulik, MD (USA)
Expert Panel: Neehar Parikh, MD (USA), Gonzalo Sapisochin, MD, PhD (Canada) and Masatoshi Kudo MD, PhD (Japan)
Speaker: Jasmine Sinha, MD (USA)

Case 1: Advanced HCC with Non Main PVT Treated with LRT + Systemic and then Transplant
Jasmine Sinha, MD (USA)

Case 2: Progression from Resection to Recurrence and Management Including Several Systemic Therapies and the Sequence of these Therapies
Jasmine Sinha, MD (USA)

15:15 – 15:45

Coffee and Networking Break

15:45 – 17:15

General Session 3: Epidemiology, Diagnosis, Staging

Chairs: Caitlin Hester, MD (USA) and Tim Meyer, MD, PhD (United Kingdom)
0-18 Evaluation of the Prognostic and Predictive Significance of Hepatocellular Carcinoma Circulating Tumor Cells Expressing Programmed Death-Ligand 1 (PD-L1)
Vatche G Agopian et al.
0-19 Addition Of 18F-Fluorodeoxyglucose (Fdg) Pet-Ct To Cross Sectional Imaging Improves Staging and Alters Management in Patients With HCC- Results From A North American Prospective Study
Binu John et al.
0-20 Hepatocellular Carcinoma Incidence is Decreasing Among Young and Middle-Aged Adults in the United States
Nicole E. Rich et al.
0-21Associations between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Primary Liver Cancer Among Women
Jessica L. Petrick et al.
0-22 A Gene Expression Signature of Microvascular Invasion in Hepatocellular Carcinoma in Formalin Fixed-Paraffin Embedded Biopsies
Aurélie Beaufrère et al.
0-33 VETC (vessels encapsulating tumor clusters) is a Powerful Predictor of Aggressive Hepatocellular Carcinoma
Luca Di Tommaso et al.

17:15 – 17:30

Session Break

16:30 – 18:30

Workshop for Advanced Practice Providers and Nurses

Chair: HoChong Gilles, DNP, FNP-BC (USA)

  • Liver Lesions 101
    Barbara Andrews, MSN, FNP-BC (USA)
  • Surgical and Locoregional Treatment Options for HCC
    HoChong Gilles, DNP, FNP-BC (USA)
  • New Systemic Therapies for Advanced HCC
    Vicki Shah, PA-C, MMS (USA)
  • Panel Discussion − Multi-Disciplinary Tumor Board: A Case-Based Approach
    HoChong Gilles, DNP, FNP-BC (USA), Barbara Andrews, MSN, FNP-BC (USA) and Vicki Shah, PA-C, MMS (USA)
  • Q&A Session
    HoChong Gilles, DNP, FNP-BC (USA), Barbara Andrews, MSN, FNP-BC (USA) and Vicki Shah, PA-C, MMS (USA)

17:30 – 18:30

ILCA Single Topic Workshops (STW)

STW 1: Molecular Diversity in HCC
Novel Models to Explore Molecular Diversity in HCC
Amaia Lujambio, PhD (USA) and Jean-Charles Nault, MD (France)

STW 2: Systemic Therapy
How to Sequence Treatment
Britsi Basu, MD, PhD (UK) and Andrew Zhu, MD, PhD (USA)

STW 3: Surgery for Primary Liver Cancer
Transplantation for Cholangiocarcinoma
Lewis Roberts, MD, PhD (USA) and Eric Vibert, MD, PhD (France)

STW 4: Radiology
Imaging of HCC Response to Loco-Regional and Systemic Therapy
Riccardo Lencioni, MD (Italy/USA) and Tae Kyoung Kim, MD, PhD (Canada)

18:30 – 19:30

Industry Partner Workshops

08:00 – 09:00

Industry Partner Symposium

09:00 – 10:15

ILCA − AASLD Symposium

Chairs: Jessica Zucman-Rossi, MD, PhD (France) and Josep M. Llovet, MD, PhD (Spain/USA)

  • End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate and Advanced HCC
    Richard Finn, MD (USA)
  • Immunotherapy for HCC: What’s Next?
    Anthony El-Khoueiry, MD (USA)
  • Pathogenesis and Systemic Management of iCCA: Role of Molecular Therapies
    Gregory Gores, MD (USA)

10:15 – 10:45

State-of-the-Art Lecture 2: Molecular Lessons Learnt from Clinical Trials in the Last Decade

Speaker: Andrew Zhu, MD, PhD (USA)

10:45 – 11:00

Coffee and Networking Break

11:00 – 12:30

General Session 4: Novel Targetsnd Prognostics Markers

Chairs: Stefanie Hectors, PhD (USA) and Andrew Zhu, MD, PhD (USA)
0-23 First-in-human, first-in-class phase I trial of MTL-CEBPA, a RNA oligonucleotide Targeting the Transcription Factor C/EBP-α, Given as a Single Agent or in Combination with Sorafenib, in Patients with Advanced Hepatocellular Cancer (HCC)
Debashis Sarker et al.
0-24 Integrated Analysis of the ceRNA Network Revealing a 4-Gene-Based Prognostic Signature Associated with Overall Survival in Hepatocellular Carcinoma
Yongcong Yan et al.
0-25 Development of Efficient Combination Immunotherapy for Primary and Metastatic Liver Cancer by Boosting Innate and Adaptive Immunity Simultaneously
Gen-Sheng Feng et al.
0-26 AU-409: Preclinical Activity Of A Novel Oral DNA Binding Agent For Hepatocellular Carcinoma
Andrew Protter et al.
0-27 The Safety and Efficacy of Namodenoson in the Second Line Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients with Underlying Child-Pugh B (CPB) Liver Cirrhosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled
Pnina Fishman et al.
0-34 Development of Novel CAR-T cells for Immunotherapy of Hepatocellular Carcinoma
Yukai He et al.

12:30 – 12:45

Closing Ceremony

Contact Us

Keep Me Updated

By continuing to browse this website, you accept cookies which are used to offer a personalized experience on our website, generate statistics and realize advertising or social network tracking. Find out more about our <a href="">Privacy & Cookie policy</a> and how to manage them on your browser. You can change your cookie settings at any time. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.